Discovery of chromenes as inhibitors of macrophage migration

inhibitory factor by Kok, Tjie et al.
Bioorganic & Medicinal Chemistry 26 (2018) 999–1005Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcDiscovery of chromenes as inhibitors of macrophage migration
inhibitory factorhttps://doi.org/10.1016/j.bmc.2017.12.032
0968-0896/ 2017 Elsevier Ltd. All rights reserved.
⇑ Corresponding author at: Antonius Deusinglaan 1, 9713AV Groningen, The
Netherlands.
E-mail address: f.j.dekker@rug.nl (F.J. Dekker).
f These authors contributed equally.Tjie Kok a,e,f, Hannah Wapenaar a,f, Kan Wang b,f, Constantinos G. Neochoritis b,f, Tryfon Zarganes-Tzitzikas b,
Giordano Proietti a, Nikolaos Eleftheriadis a,c, Katarzyna Kurpiewska d, Justyna Kalinowska-Tłus´cik d,
Robbert H. Cool a, Gerrit J. Poelarends a, Alexander Dömling b, Frank J. Dekker a,⇑
aDepartment of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands
bDepartment of Drug Design, University of Groningen, Groningen, The Netherlands
cMolecular Microscopy Research Group, Zernike Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands
d Faculty of Chemistry, Jagiellonian University, 3 Ingardena Street, 30-060 Kraków, Poland
e Faculty of Biotechnology, University of Surabaya, Jalan Raya Kalirungkut, Surabaya 60292, Indonesia
a r t i c l e i n f oArticle history:
Received 16 November 2017
Revised 20 December 2017
Accepted 22 December 2017
Available online 24 December 2017
Keywords:
Macrophage migration inhibitory factor
Chromenes
Inhibitor
Enzyme kineticsa b s t r a c t
Macrophage migration inhibitory factor (MIF) is an essential signaling cytokine with a key role in the
immune system. Binding of MIF to its molecular targets such as, among others, the cluster of differenti-
ation 74 (CD74) receptor plays a key role in inflammatory diseases and cancer. Therefore, the identifica-
tion of MIF binding compounds gained importance in drug discovery. In this study, we aim to discover
novel MIF binding compounds by screening of a focused compound collection for inhibition of its tau-
tomerase enzyme activity. Inspired by the known chromen-4-one inhibitor Orita-13, a focused collection
of compounds with a chromene scaffold was screened for MIF binding. The library was synthesized using
versatile cyanoacetamide chemistry to provide diversely substituted chromenes. The screening provided
inhibitors with IC50’s in the low micromolar range. Kinetic evaluation suggested that the inhibitors were
reversible and did not bind in the binding pocket of the substrate. Thus, we discovered novel inhibitors of
the MIF tautomerase activity, which may ultimately support the development of novel therapeutic agents
against diseases in which MIF is involved.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
Macrophage migration inhibitory factor (MIF) is a central cyto-
kine of the immune system. It is expressed in immune cells such as
T-cells, macrophages, basophiles, eosinophils and B-cells.1 Unlike
other cytokines, MIF is constitutively expressed and stored in cyto-
plasmic pools and rapidly released in response to stimuli.2 Upon
release, MIF interacts with surface receptors on B-cells, T-cells,
macrophages and some epithelial cells, which induce pro-inflam-
matory signal transduction. MIF has been shown to interact with
the type II cluster of differentiation 74 (CD74) receptor, which is
the invariant chain of the major histocompatibility complex II
(MHCII). CD74 does not seem to have an intracellular signaling
domain and is, therefore, expected to initiate intracellular signaling
by recruiting other membrane receptors such as CD44, CXCR2 andCXCR4.3–5 These interactions are important for the role of MIF in
inflammatory signaling. In addition, MIF has also been suggested
as a target in cancer due to its downregulation of p53 and its over-
expression in several cancer cell types.6–10 It was shown that neu-
tralization of MIF through antibodies or genetic deletion was
beneficial in several inflammatory disease models and a small
molecule inhibitor of MIF was able to reduce tumor growth in
mouse models.11–15 Taken together these data indicate that devel-
opment of MIF binding molecules has potential for drug discovery
for inflammatory diseases and cancer.
MIF is a small protein of 115 amino acids, weighing approxi-
mately 12.4 kDa and exists predominantly in a homotrimeric form.
One human homologue has been described, D-dopachrome Tau-
tomerase (D-DT or MIF2), which shows a similar function to
MIF.16 MIF has structural similarity to two bacterial enzymes:
4-oxalocrotonate tautomerase (4-OT) and 5-carboxymethyl-2-
hydroxymuconate isomerase.17 Inspired by these similarities, it
was discovered that MIF not only functions as a cytokine, but has
enzymatic activity as well. It has been shown to catalyze the inter-
conversion of enol and keto isomers of D-Dopachrome and
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activity is the N-terminal proline which acts as a catalytic base in
the tautomerase reaction.19 Screening for inhibitors of MIF tau-
tomerase activity has been recognized as an efficient way to iden-
tify MIF binding compounds that can be further investigated in
more advanced disease models where MIF has been shown to play
a role. A well-known inhibitor of the MIF tautomerase activity is
the isoxazoline (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxa-
zole acetic acid methyl ester (ISO-1, Fig. 1). ISO-1 is a competitive
inhibitor of the MIF tautomerase activity and has beneficial effects
in several disease models such as sepsis, chronic obstructive pul-
monary disease (COPD) and cancer.15,20–23 Based on ISO-1, several
other MIF inhibitors have been developed, among which are the
biaryltriazoles.24–28 Using a structure-based virtual screening
method, Orita-13 containing a chromen-4-one scaffold was identi-
fied as MIF inhibitor.26,29 Additionally, covalent MIF inhibitors have
been described, such as TP, as probes suitable for activity-based
protein profiling.30 Taken together, several small molecule binders
of MIF have been developed (Fig. 1), but the identification of novel
structural classes remains needed for a better understanding of the
structural requirements for binding and to provide a broader basis
for drug discovery.
Here, we describe the identification of novel MIF binders
inspired by the chromen-4-one scaffold of Orita-13. A focused
compound collection of 57 compounds was synthesized using
cyanoacetamide-based chemistry. Screening of this library for inhi-
bition of MIF tautomerase activity provided 6 inhibitors with
potencies in the low micromolar range. The structural motif that
was identified expands the number of scaffold available for further
development of MIF inhibitors towards applications in disease
models.2. Materials and methods
2.1. Chemistry general
All the reagents and solvents were purchased from Sigma-
Aldrich, AK Scientific, Fluorochem, Abcr GmbH, or Acros and were
used without further purification. All microwave irradiation reac-
tions were carried out in a Biotage InitiatorTM Microwave Synthe-
sizer. Thin layer chromatography was performed on Millipore
precoated silica gel plates (0.20 mm thick, particle size 25 lm).
Nuclear magnetic resonance spectra were recorded on Bruker
Avance 500 or 600 spectrometers 1H NMR (500 MHz; 600 MHz),
13C NMR (126 MHz; 151 MHz). Chemical shifts for 1H NMR were
reported as d values and coupling constants were in hertz (Hz).
The following abbreviations were used for spin multiplicity: s =
singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet,
quin = quintet, dd = doublet of doublets, ddd = doublet of doublet
of doublets, m = multiplet. Chemical shifts for 13C NMR were
reported in ppm relative to the solvent peak. Flash chromatogra-
phy was performed on a Reveleris X2 Flash Chromatography sys-
tem, using Grace Reveleris Silica flash cartridges (12 g). MassFig. 1. Known MIF tautomerase activity inhibitors ‘‘ISO-1”, a ‘‘spectra were measured on a Waters Investigator Supercritical Fluid
Chromatograph with a 3100 MS Detector (ESI) using a solvent sys-
tem of methanol and CO2 on a Viridis silica gel column (4.6 x 250
mm, 5 mm particle size) or Viridis 2-ethyl pyridine column (4.6 
250 mm, 5 mm particle size). High resolution mass spectra were
recorded using a LTQ-Orbitrap-XL (Thermo) at a resolution of
60,000@m/z400.
2.2. General procedure for the synthesis of 1–57
To a stirred solution of 2H-chromen-2-one (1.0 mmol) in dry
ethanol (5 mL), the corresponding cyanoacetamide (1.0 mmol)
and sodium ethoxide (0.2 mmol) were added. The reaction mixture
was stirred at room temperature for 24 h. The precipitate was fil-
tered off and washed with cold ethanol (2  5 mL), yielding the
final compounds without further purification in yields ranging
from 35 to 81%. The characterization of all compounds can be
found in the supporting information.
2.3. Single crystal x-ray structure determination
X-ray diffraction data for a single crystal of compound 7 was
collected using a SuperNova (Rigaku-Oxford Diffraction) four circle
diffractometer with a mirror monochromator and a microfocus
MoKa radiation source (k = 0.71073 Å). Additionally, the diffrac-
tometer was equipped with a CryoJet HT cryostat system (Oxford
Instruments) allowing low temperature experiments, performed
at 130 (2) K. The obtained data was processed with CrysAlisPro
software (S1). The phase problem was solved by direct methods
using SIR2004 (S2). Parameters of models were refined by full-
matrix least-squares on F2 using SHELXL-2014/6 (S3). Calculations
were performed using WinGX integrated system (ver. 2014.1) (S4)
Figure was prepared with Mercury 3.7 software (S5).
All non-hydrogen atoms were refined anisotropically. All hydro-
gen atoms attached to carbon atoms were positioned with the ide-
alised geometry and refined using the riding model with the
isotropic displacement parameter Uiso[H] = 1.2 (or 1.5 (methyl
groups only)) Ueq[C]. Positions of hydrogen atoms linked to N2
were defined on the difference Fourier map and refined with no
additional restraints. Crystal data and structure refinement results
for presented crystal structure are shown in Table S1. The molecu-
lar geometry (asymmetric unit) observed in the crystal structure is
shown in Fig. S1. Crystallographic data have been deposited with
the Cambridge Crystallographic Data Centre as supplementary
publication No. CCDC 1575884.
2.4. MIF tautomerase activity assay
Tautomerase activity inhibition of MIF by the synthesized
chromene compounds was measured using recombinantly
expressed His-tagged MIF, which was purified with cOmplete
His-Trap purification resin (Roche, The Netherlands). The assay
was done following the procedure of Dziedzic et al.26 4-hydrox-biarylatriazole”, ‘‘Orita-13” and activity-based probe ‘‘TP”.
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tomerase activity. Stock solutions of 10 mM 4-HPP were made in
50 mM ammonium acetate buffer pH 6.0, and incubated over-
night at room temperature to allow equilibration between keto
and enol form. Further dilutions of the substrate were made in
the same acetate buffer. Inhibitor stock solutions had a concen-
tration of 10 mM in DMSO. The inhibitor stock solutions were
diluted in 0.4 M boric acid pH 6.2 to give final concentration in
the screening assay of 25 and 50 mM. For the IC50 assay final con-
centrations of 250–0 mM or 100–0 mM or 25–0 mM in 5% DMSO,
with 2 or 1.6-fold dilution series were applied. The control con-
tained 5% DMSO as a vehicle control. This amount did not influ-
ence the MIF tautomerase activity. In the assays 50 mL of
mixtures of MIF (dilution in 0.2 M boric acid pH 6.2, to give a final
concentration of 340 nM) and the synthesized compounds were
put in a UV-star F bottom 96-well plate. The enzymatic reaction
was started by addition of 50 mL 4-HPP (to give a final concentra-
tion of 0.5 mM), and the increase of absorbance at 306 nm was
followed over time using a Spectrostar Omega BMG Labtech plate
reader. The positive control contained all the components exclud-
ing inhibitor (but including 5% DMSO), and the negative control
was as the positive control without MIF. The data obtained were
analyzed by firstly taking the slopes of the linear part of the
increased absorbance over the time (that is the velocity of the
enzymatic reaction), then normalizing them to the positive and
negative control to give percentage of inhibition.2.5. Enzyme kinetic evaluation
To evaluate the reversibility of MIF tautomerase inhibition by
the discovered chromene inhibitors, preincubation experiments
were conducted using inhibitor 10 and 17. The inhibitors (125–0
mM, 1.6-fold dilution series in 5% DMSO) were preincubated with
the enzyme (340 nM) for 2 min (the time of preincubation in the
regular IC50 assays) and 40 min prior to adding the substrate and
starting the enzymatic reaction. Then the IC50 curves were made
as described above.
Dilution experiments were performed using inhibitor 10. To do
this, an initial mixture with a relatively high concentration of MIF
(34 mM) and the inhibitor (125 mM in 5% DMSO) was made. Subse-
quently, this mixture was diluted 100 times in a solution contain-
ing the substrate 4-HPP (0.5 mM) and boric acid. A control assay
was done following the same procedure without inhibitor, but con-
taining 5% DMSO. The enzyme activity was measured as described
before. The absorbance was plotted against time.Fig. 2. A) Synthesis of fused amino-2H-chromenopyridine-diones. B) Stereoscopic view o
scaffold (cyan). C) Structure of compound 7, Molecular geometry observed in the crystal s
hydrogen bond between the exocyclic amine and the carbonyl group is formed.To further investigate the mechanism of inhibition, kinetic
experiments were conducted using inhibitor 10. The velocity of
the enzymatic reaction was measured at increasing concentrations
of 4-HPP (0–2.56 mM, 1.25  dilution) in the presence of MIF (340
nM) and inhibitor (0, 6.25 or 12.5 mM). The velocity of the reaction
was plotted against the concentration of 4-HPP using GraphPad
Prism 5.0. The curve was plotted using enzyme kinetics-allosteric
sigmoidal, yielding the Vmax app., Hill slope and Kprime app. The con-
centration of 4-HPP that gives half of Vmax (Khalf) was calculated
from the Kprime using the following equation:
Khalf ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
KprimeHillslope
p3. Results and discussion
3.1. Chemistry
A library of approximately 60 fused amino-2H-chromenopy-
ridine-diones was synthesized using methods as initially described
by Rosati et al. (Fig. 2A).31,32 The alignment of Orita-13 with the
amino-2H-chromenopyridine-dione scaffold can be detected by
checking the stereoscopic view of Orita-13, which indicates the
potential of this library for MIF binding (Fig. 2B). These scaffolds
combine a series of interesting features besides the chromene core,
such as the amino group in 5-position and a fused piperidinodione
ring. Moreover, the possibility to increase the diversity with two
points of diversification and the rigid core structure attributed to
the selection of this scaffold. It was possible to get the crystal struc-
ture of compound 7 revealing an intramolecular hydrogen bond
between the exocyclic amine and the carbonyl group. This led to
coplanarity between the fused rings, which provides interesting
possibilities for the type of interactions under investigation (Fig.
2C, Fig. S1, Scheme S1).
Starting from our broad experience with cyanoacetamide chem-
istry in heterocycle synthesis,33–36 we elaborated on the synthesis
of Rosati et al.,31 using a number of different cyanoacetamides and
suitably substituted 2H-chromenes. Thus, we designed and synthe-
sized a highly diverse medium-sized library in a medicinal chem-
istry frame utilizing aliphatic and aromatic substituents,
heterocycles, hydrogen bond donors and acceptors. In addition,
we enhanced the solubility of specific compounds with the intro-
duction of morpholino substituents. The reactions proceeded
under mild conditions with a plethora of different cyanoac-
etamides in good to very good yields in a parallel manner.f the 3D-alignment of Orita-13 (green) with the amino-2H-chromenopyridine-dione
tructures of compound 7, showing the atom labelling scheme and an intramolecular
Table 1
Inhibition of MIF tautomerase activity by synthesized compounds of a chromene scaffold and reference compound ISO-1. IC50 values were given as mean ± standard deviation of
at least 2 independent experiments. ND = not determined.
Compound R1 % inhibition at 25 mM IC50 (mM) Compound R1 R2 % inhibition at 25 mM IC50 (mM)
1 40% ND 9 3-OEt 60% 21 ± 2.1
2 10% ND 10 H 60% 18 ± 3.5
3 10% ND 11 4-Me 50% ND
4 80% 7.1 ± 1.0 12 H 15% ND
5 15% ND 13 3-Me 5% ND
6 45% ND 14 3-OEt 10% ND
7 80% 13 ± 1.1 15 H 15% ND
8 70% 8.0 ± 1.0 16 4-Me 25% ND
ISO-1 79 ± 3.7 17 3-Me 55% 6.2 ± 0.6
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The compounds were tested for inhibition of the MIF tau-
tomerase activity using a spectrophotometric assay based on the
absorbance detection of the enzymatic enol product of 4-hydroxy
phenylpyruvate (4-HPP) after reaction with boric acid.26 First, a
single point screening was done at a concentration of 25 mM and
50 mM and the compounds showing more than 50% inhibition of
enzyme activity at 25 mM were tested for IC50 values (Figs. S2
and S3).
The investigation started with 4-chlorobenzyloxy chromene
derivatives, bearing various aliphatic or aromatic substituents on
the R1 position (compounds 1–8, Table 2). Short aliphatic sub-
stituents (1–3) showed less than 50% inhibition at 25 mM, whereas
compound 4 carrying a longer aliphatic substituent provided an
IC50 of 7.1 ± 1.0 mM. The compounds with aromatic substituent
(5–8) also showed inhibition, of which a 4-chlorophenethyl sub-
stituent (7, IC50 = 13 ± 1.1mM) and an indole with ethyl spacer (8,
IC50 = 8.0 ± 1.0 mM) gave the best results. This suggests that lipo-
philic interactions are important for the inhibition of MIF. Next,
these active derivatives (4, 7 and 8) were further investigated. To
investigate whether the bulky 4-chlorobenzyloxy was necessary,
it was removed (R2 = H) or replaced with several smaller sub-
stituents such as 3-Me, 4-Me or 3-OEt on the R2 position (Table 1).
In case of the long dodecane substituent (9–11), when smaller sub-
stitutions on position R2 were introduced, activity did not improve.
In contrast, introducing smaller substitutions on R2 in case of com-
pounds with a 4-chlorophenethyl on position R1 (12–13) caused a
loss of activity. Concerning the indole substituted compounds (14–
17), a methyl substituent at R2 improved slightly the activity, but
others were not active. Several other compounds were synthesizedcombining different types of substituents at the R1 position, such
as morpholines, naphthalenes, furans, thiophenes or aliphatic
chains with different heteroatoms (Table 2), but these did not lead
to an improved inhibition. The IC50 value of reference MIF inhibitor
ISO-1 was determined under the conditions used for the chromene
compounds. The IC50 value of ISO-1 was within the range reported
in literature.37 The activity of Orita-13 has been reported to be sim-
ilar to ISO-1.27 The most potent chromene compounds were active
at lower concentrations compared to the reference compound ISO-
1. Therefore, compounds 10 and 17 were taken for further
investigation.
3.3. Kinetic evaluation
To investigate the reversibility of the inhibition of MIF by the
discovered inhibitors, a preincubation assay was performed with
10 and 17. The inhibitors were preincubated with MIF for 2 or
40 min before initiating the enzymatic reaction. Then, the IC50
curve was made as described before. No difference in IC50 was
observed between incubation times, suggesting that the inhibition
was not time-dependent on the investigated time scale (Fig. 3A,
Fig. S4). To further investigate reversibility we performed dilution
experiments with compound 10 in which the inhibitor and enzyme
were preincubated at a high concentration (10  IC50) before dilu-
tion in a substrate solution to 10 below the IC50 of the inhibitor.
In combination with an irreversible inhibitor, the enzyme will
show no activity after dilution. With a reversible inhibitor, how-
ever, the activity of the enzyme can be recovered.38 The dilution
assay with compound 10 showed that the activity of MIF could
be recovered after dilution (Fig. 3B), which is consistent with
reversible inhibition as observed in the preincubation assay.
Table 2
Additional chromene compounds tested for inhibition of MIF. Percentage inhibition at 25 mM is given as mean of at least 2 independent experiments.
Compound R1 R2 % inhibition at 25 mM Compound R1 R2 % inhibition at 25 mM
8 3-OEt 30% 38 3-OMe 0%
19 4-Me 20% 39 H 0%
20 3-Me 20% 40 4-Me 15%
21 3-OEt 10% 41 3-OMe 15%
22 3-OMe 15% 42 4-Me 10%
23 4-Me 0% 43 3-OEt 0%
24 3-OMe 0% 44 3-OMe 0%
25 3-Me 0% 45 4-Me 0%
26 3-OEt 0% 46 3-Me 0%
27 3-OMe 0% 47 3-OEt 10%
28 4-Me 0% 48 3-OMe 0%
29 3-OMe 0% 49 4-Me 0%
30 H 0% 50 3-OEt 0%
31 4-Me 0% 51 3-OMe 0%
32 3-OEt 0% 52 H 0%
33 3-OMe 0% 53 4-Me 10%
34 3-Me 0% 54 3-Me 0%
35 3-OMe 0% 55 3-OEt 50%
(continued on next page)
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Table 2 (continued)
Compound R1 R2 % inhibition at 25 mM Compound R1 R2 % inhibition at 25 mM
36 3-Me 0% 56 3-OMe 25%
37 4-Me 0% 57 3-Me 35%
Fig. 3. A) MIF (340 nM) was preincubated with compounds 10 (125–0 mM) for 2 or 40 min prior to starting the enzyme reaction by adding the substrate. No significant change
in IC50 value was observed. B) MIF (34 mM) was incubated with a concentration of 125 mM of compound 10. Subsequently, this mixture was diluted 100x with the substrate
and the enzyme activity was monitored. Diluting the inhibitor recovered the enzyme activity. C) The velocity of the enzyme reaction was measured at increasing
concentrations of the substrate (4-HPP) in the presence of different concentrations of inhibitor 10. The Vmax app., Hill slope and Khalf app. were determined for each inhibitor
concentration.
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inhibitors, a kinetic evaluation of compound 10 was done
(Fig. 3C). The velocity of the enzyme reaction was measured at
increasing concentrations of the substrate (4-HPP) in the
presence of different concentrations of inhibitor 10. From this
curve, the apparent maximum velocity (Vmax app.), the Hill slope
and the concentration of 4-HPP that gave half of Vmax app.
(Khalf app.) were determined. The experiment showed a sigmoidal
curve with a Hill slope larger than 1, not following Michaelis-
Menten kinetics, which is in line with observations from Lubet-
sky et al.39 The Khalf values were consistent with the values
reported by Lubetsky et al. (denoted as [S]0.5). An increasing
concentration of compound 10 gave a decrease in Vmax app.
The change in Khalf app. is less pronounced. This indicates that
there is no direct competition between the substrate 4-HPP
and the inhibitor 10. This observation is in contrast to the bind-
ing mode described for Orita-13 that has been shown to bind
the MIF active site.294. Conclusions and future perspectives
MIF binding to its molecular targets plays a key role in inflam-
matory processes and cancer. Therefore, MIF binders are consid-
ered to be potential therapeutics. In this study, we employed the
MIF tautomerase enzymatic activity to identify MIF binding com-
pounds that could potentially interfere with MIF functions. Using
cyanoacetamide chemistry a focused compound collection with a
chromene scaffold was synthesized and subsequently screened
for inhibition of MIF tautomerase activity. This enabled identifica-
tion of several novel MIF inhibitors with IC50’s in the low micromo-
lar range. Kinetic evaluation suggested that compound 10 and 17
were reversible inhibitors and that inhibitor 10 does not bind in
direct competition with the substrate 4-HPP. Taken together, a
novel structural class of MIF inhibitors has been identified that
could be used to further investigate the tautomerase activity of
MIF and may ultimately lead to the development of novel thera-
peutic agents.
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